|
1
|
Beaumont A and Whittle IR: The
pathogenesis of tumor associated epilepsy. Acta Neurochir (Wien).
142:1–15. 2000. View Article : Google Scholar
|
|
2
|
Govori V, Humolli I, Cepreganov M,
Dedushaj I and Gjikolli B: Brain tumors and epilepsy. Acta Clin
Croat. 49:133–138. 2010.PubMed/NCBI
|
|
3
|
Rosati A, Tomassini A, Pollo B, Ambrosi C,
Schwarz A, Padovani A and Bonetti B: Epilepsy in cerebral glioma:
timing of appearance and histological correlations. J Neurooncol.
93:395–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roux FX and Nataf F: Cerebral
oligodendrogliomas in adults and children. Current data and
perspectives. Neurochirurgie. 51:410–414. 2005.(In English and
French).
|
|
5
|
No authors listed: Proposal for revised
classification of epilepsies and epileptic syndromes. Commission on
Classification and Terminology of the International League Against
Epilepsy. Epilepsia. 30:389–399. 1989.PubMed/NCBI
|
|
6
|
No authors listed: Proposal for revised
clinical and electroencephalographic classification of epileptic
seizures. From the Commission on Classification and Terminology of
the International League Against Epilepsy. Epilepsia. 22:489–501.
1981.PubMed/NCBI
|
|
7
|
Nicolson A, Appleton RE, Chadwick DW and
Smith DF: The relationship between treatment with valproate,
lamotrigine, and topiramate and the prognosis of the idiopathic
generalised epilepsies. J Neurol Neurosurg Psychiatry. 75:75–79.
2004.PubMed/NCBI
|
|
8
|
Posner EB, Mohamed K and Marson AG:
Ethosuximide, sodium valproate or lamotrigine for absence seizures
in children and adolescents. Cochrane Database Syst Rev.
4:CD0030322005.
|
|
9
|
French JA, Kanner AM, Bautista J,
Abou-Khalil B, Browne T, Harden CL, et al: Efficacy and
tolerability of the new anti-epileptic drugs I: treatment of new
onset epilepsy: report of the Therapeutics and Technology
Assessment Subcommittee and Quality Standards Subcommittee of the
American Academy of Neurology and the American Epilepsy Society.
Neurology. 62:1252–1260. 2004.
|
|
10
|
Kalita J, Nair PP and Misra UK: A
clinical, radiological and outcome study of status epilepticus from
India. J Neurol. 257:224–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meierkord H, Boon P, Engelsen B, Göcke K,
Shorvon S, Tinuper P, et al: EFNS guideline on the management of
status epilepticus in adults. Eur J Neurol. 17:348–355. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinha S, Satishchandra P, Mahadevan A,
Bhimani BC, Kovur JM and Shankar SK: Fatal status epilepticus: a
clinico-pathological analysis among 100 patients: from a developing
country perspective. Epilepsy Res. 91:193–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ben-Menachem E and Falter U: Efficacy and
tolerability of levetiracetam 3000 mg/d in patients with refractory
partial seizures: a multicenter, double-blind, responder-selected
study evaluating monotherapy. European Levetiracetam Study Group.
Epilepsia. 41:1276–1283. 2000. View Article : Google Scholar
|
|
14
|
Cereghino JJ, Biton V, Abou-Khalil B,
Dreifuss F, Gauer LJ and Leppik I: Levetiracetam for partial
seizures: results of a double-blind, randomized clinical trial.
Neurology. 55:236–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shorvon SD, Löwenthal A, Janz D, Bielen E
and Loiseau P: Multicenter double-blind, randomized,
placebo-controlled trial of levetiracetam as add-on therapy in
patients with refractory partial seizures. European Levetiracetam
Study Group Epilepsia. 41:1179–1186. 2000.PubMed/NCBI
|
|
16
|
Abou-Khalil B, Hemdal P and Privitera MD:
An open-label study of levetiracetam at individualised doses
between l000 and 3000 mg day(−1) in adult patients with refractory
epilepsy. Seizure. 12:141–149. 2003.PubMed/NCBI
|
|
17
|
Bemn RG, Berkovic SF, Black AB, Danta G,
Hiersemenzel R, Schapel GJ and Vajda FJ: Efficacy and safety of
levetiracetam 1000–3000 mg/day in patients with refractory
partial-onset seizures: a multicenter, open-label single-arm study.
Epilepsy Res. 63:1–9. 2005.
|
|
18
|
Morrell MJ, Leppik I, French J,
Ferrendelli J, Han J and Magnus L: The KEEPER trial: levetiracetam
adjunctive treatment of partial-onset seizures in an open-label
community-based study. Epilepsy Res. 54:l53–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kälviäinen R, Eriksson K and Parviainen I:
Refractory generalised convulsive status epilepticus: a guide to
treatment. CNS Drugs. 19:759–768. 2005.PubMed/NCBI
|
